SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending as it faces a wave of analyst downgrades and intense investor frustration over its prolonged stock underperformance, despite a low valuation and active share buyback program. While many criticize current management and see it as 'dead money,' a bullish segment argues the fintech giant is significantly undervalued, poised for a rebound as it solidifies its position in digital payments and the evolving 'buy now, pay later' market.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd

SU Group Holdings Ltd (SUGP) is trending as community discussion highlights its ultra-low share float and significant short interest, creating strong speculation for a potential short squeeze. Traders are actively drawing comparisons to past high-volatility runners like SMX, fueled by its presence on the Reg SHO list, high cost to borrow, and anticipation of upcoming earnings and contract news as potential catalysts.

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

Biodesix Inc

Biodesix (BDSX) is trending after announcing preliminary quarterly and full-year results that significantly beat revenue expectations, sparking strong bullish sentiment across the community. Investors are keenly discussing the impressive growth, coupled with high analyst price targets and the potential for a rally driven by the stock's low free float. However, some continue to voice concerns regarding the company's cash reserves and the ongoing risk of dilution.

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Atara Biotherapeutics Inc

Atara Biotherapeutics (ATRA) is trending following a second FDA Complete Response Letter for its EBVALLO cancer therapy, which now cites concerns over clinical trial design despite previously resolved manufacturing issues. The community is expressing significant frustration over the FDA's unexpected change in position and questioning the need for a new trial, especially given the drug's existing approval in Europe.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is actively trending as its advanced agentic and voice AI technology showcased at a recent major tech conference generated significant buzz, leading to new partnerships in the automotive and robotics sectors. The community is heavily discussing the stock's high short interest, anticipating a potential squeeze, and highlighting its strong revenue growth and strategic position within the expanding AI market.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony is trending amidst escalating geopolitical tensions, particularly concerning critical minerals and China's tightening export restrictions, positioning the company as a crucial domestic supplier for defense. The community is actively discussing its role as the sole North American integrated antimony producer for the U.S. military and anticipating significant government investment to secure national supply chains. Sentiment remains highly bullish, with many seeing the company as undervalued given its strategic importance and expected contract expansions.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is generating significant buzz as investors anticipate a major re-rating for Chinese tech, driven by the company's accelerating AI and cloud growth and strategic investments in startups like MiniMax. The community is actively discussing a potential technical breakout and short squeeze, fueled by the belief that the stock is deeply undervalued and poised for substantial upside as the narrative shifts towards China's AI dominance.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending following recent developments, including Amazon Pharmacy's launch of Novo Nordisk's oral GLP-1 weight loss pill which is notably unavailable on HIMS's platform, compounded by an analyst downgrade citing elevated 2026 investment outlook. This has ignited a split in community sentiment, with many questioning HIMS's competitive moat, while others actively buy the dip, asserting confidence in the company's broader personalized healthcare platform and vertical integration for long-term growth.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs is trending amidst a significant multi-year, nine-figure agreement with the Swedish Armed Forces, underscoring its robust demand for satellite services and fueling community excitement. Investors are actively discussing the company's growing backlog and strategic collaborations, such as 'Project Suncatcher' with Google for AI-enabled space data, as the broader space sector experiences accelerating momentum.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivax (ABVX) is trending due to heightened speculation surrounding a potential takeover by Eli Lilly and other major pharmaceutical companies, with reports from French media and government sources fueling the buzz. The community is actively discussing an impending bidding war and significant premiums for its promising ulcerative colitis drug, obefazimod, which has demonstrated strong Phase 3 data. This innovative treatment positions Abivax as a highly attractive target in the competitive inflammatory bowel disease market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Eli Lilly has not yet submitted a formal bid for Abivax.</li><li>In an interview with Bloomberg, Abivax CEO Marc de Garidel stated that a Treasury review is necessary in France and typically takes up to three months.</li><li>Garidel added that major pharma companies can no longer ignore Abivax’s experimental drug for inflammatory bowel disease, obefazimod.</li></ul>Abivax SA’s (ABVX) American Depository Receipts (ADRs) soared more than 32% in Monday’s pre-market trade after reports stated that U.S. pharmaceutical giant Eli Lilly &amp; Co. (LLY) is interested in acquiring the French biotechnology company.According to a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.lalettre.fr/fr/entreprises_sante/2026/01/12/eli-lilly-pret-a-mettre-15-milliards-d-euros-sur-la-table-pour-la-biotech-abivax,110595898-eve">report</a> by La Lettre on Monday, Eli Lilly is said to be ready to acquire Abivax for €15 billion ($17.5 billion), which is nearly twice the current market capitalization of the French biotech company.Retail sentiment on Stocktwits about Abivax SA was in the ‘bullish’ territory, with the ticker among the top 10 trending symbols on the platform at the time of writing.<a href="https://stocktwits.com/symbol/ABVX">Eli Lilly shares</a> were up nearly 1% in Monday’s pre-market trade.<h2 class="st-heading-2">Eli Lilly’s Interest In Abivax</h2>The report added that Eli Lilly is awaiting guidance from France’s Finance Ministry to understand if an acquisition of Abivax would be subject to foreign investment controls.Eli Lilly has not yet submitted a formal bid for Abivax. In an&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-01-12/abivax-ceo-says-big-pharma-can-t-ignore-its-experimental-drug">interview</a> with Bloomberg, Abivax CEO Marc de Garidel stated that a Treasury review is necessary in France and typically takes up to three months.<h2 class="st-heading-2">Abivax’ Experimental Drug</h2>Garidel added that major pharma companies can no longer ignore Abivax’s experimental drug for inflammatory bowel disease, obefazimod.“If you are Big Pharma, you cannot ignore that this product may be one of the most-used products in the next decade,” he added in the interview.In a separate&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.biotechtv.com/post/marc-de-garidel-abivax-january-11-2026">interview</a> with BiotechTV, Garidel stated that Abivax is focusing on developing the drug and bringing it to the market, while adding that he has no control over the rumors and speculation surrounding the company.<h2 class="st-heading-2">Price Target Hikes Pour In</h2>Analysts at Morgan Stanley and BTIG hiked their price targets for Abivax, according to TheFly. Morgan Stanley hiked its price target for ABVX to $145 from $101, while maintaining its ‘Overweight’ rating on the stock.Analysts at BTIG hiked their price target to $150 from $120, while keeping a ‘Buy’ rating on Abivax shares.Both firms cited optimism around Abivax’s obefazimod, with Morgan Stanley analysts stating that experts are increasingly encouraged by both the magnitude of effect and tolerability profile demonstrated in the induction portion of the Phase 3 program.<a href="https://stocktwits.com/symbol/ABVX">ABVX ADR</a> is down 17% year-to-date, but up 1,693% over the past 12 months.&nbsp;<a href="https://stocktwits.com/symbol/ABVX">LLY stock</a> is down 1% YTD, but up 35% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/xom-stock-declines-after-trump-threatens-sidelining-exxon-mobil-venezuela/cmU9wSrR43D">XOM Stock Falls Pre-Market After Trump Reportedly Signals Venezuela Exclusion – Retail Sentiment Sours</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Abivax logo is seen displayed on a smartphone screen

ABVX Soars Pre-Market On Reports Of $17.5 Billion Eli Lilly Takeover Interest

Eli Lilly is awaiting guidance from France’s Finance Ministry to understand if an acquisition of Abivax would be subject to foreign investment controls.

Equity

Biotech Stocks Worth Watching - January 8th

Cidara Therapeutics, Abivax, and Vertex Pharmaceuticals are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded...

Abivax (NASDAQ:ABVX) Shares Down 8.7% - Here's Why

Abivax (NASDAQ:ABVX) Shares Down 8.7% - Here's Why...

Biotech Stocks To Watch Today - January 3rd

Danaher, Vertex Pharmaceuticals, Cidara Therapeutics, Moderna, United Therapeutics, argenex, and Abivax are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool...

Best Biotech Stocks To Follow Now - January 1st

Vertex Pharmaceuticals, Danaher, Abivax, Moderna, and United Therapeutics are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of...

Best Biotech Stocks To Follow Today - December 31st

Abivax, Danaher, and Cogent Biosciences are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that research, develop and...

Voya Investment Management LLC Invests $978,000 in Abivax SA Sponsored ADR $ABVX

Voya Investment Management LLC purchased a new stake in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX - Free Report) during the third quarter, according to the company in its most recent 13F filing...

Stock Traders Purchase Large Volume of Abivax Call Options (NASDAQ:ABVX)

Abivax SA Sponsored ADR (NASDAQ:ABVX - Get Free Report) was the target of unusually large options trading activity on Tuesday. Traders acquired 6,598 call options on the company. This is an increase...

Biotech Stocks To Watch Today - December 30th

Abivax, Danaher, and Amicus Therapeutics are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies that...

Abivax (NASDAQ:ABVX) Trading Down 4% - Should You Sell?

Abivax (NASDAQ:ABVX) Stock Price Down 4% - Time to Sell...

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Stocktwits

Stocktwits Polls

Widespread speculation surrounds a potential $17.5 billion acquisition by Eli Lilly, prompting discussions about share prices around $200-$220.

Debates intensify over a major fund's share sale via Form 144, with users discussing whether it's routine profit-taking or a buying opportunity on the dip.

The stock experienced substantial pre-market gains and volatility due to acquisition reports, reaching levels near $145 and even a trading halt on Euronext.

Positive Phase 3 data for its ulcerative colitis drug continues to underpin long-term confidence and expectations of it becoming a market leader.

Current Price	$119.43
Prev Close	$114.40
Open	$121.45
Dividend Yield	0.00%
50-Day Moving Average	$118.06
Beta	0.80
Avg. Volume	1.89M
PE Ratio	-37.83

52-Week High	$148.83
52-Week Low	$4.77
Market Capitalization	$8.97B
EPS (Annual)	-$3.02
Price to Book	14.82
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

ABVX
Abivax - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ABVX News

ABVXAbivax - ADR